Developer docs
API playgroundTry for free, no card

Search company profiles

RealView Imaging

Full company profile

uuid0002p3c

Namestring
RealView Imaging
Legal namestring
RealView Imaging Ltd.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RealView Imaging Ltd. is an Israeli medical technology company that has developed the world's first commercial 3D holographic display and interface system for medical imaging, anchored by its FDA-cleared HOLOSCOPE-i system. The company's core technology, Digital Light Shaping™, uses interference-based holography (originating from Nobel Prize-winning holography principles) together with Spatial Light Modulators to generate real-time, full-color, high-resolution 3D holograms in free space at hand-reach, eliminating the vergence-accommodation conflict associated with stereoscopic AR headsets. A complementary capability branded "Image Intimacy™" allows physicians to directly touch, rotate, slice, mark, and measure within the holographic image using Intel RealSense depth sensors.

The company's product portfolio is highly focused: the HOLOSCOPE-i system is the single commercial product, targeted at interventional cardiology procedures (catheterization, structural heart disease treatment, pre-surgical planning, and intra-procedural imaging guidance) in hospitals' interventional suites, hybrid operating rooms, and cardiac catheterization labs. A secondary target segment includes diagnostic clinics and medical education institutions needing advanced 3D visualization. Clinical validation has been supported by a first-in-human study conducted with Philips Healthcare.

RealView operates a direct enterprise sales motion, selling capital equipment to hospitals and clinical institutions, supplemented by ongoing customer support and service contracts (evidenced by a registered customer portal). The company is headquartered in Yokneam Illit, Israel, employs 11-50 people, and has raised approximately $25M across a 2014 Series B (LongTec China Ventures, $10M) and a 2020-2021 Series C (initial $10M from OurCrowd, expanded to $15M following FDA clearance). Geographic reach as of 2024 extends to Israel, the United States, and a newly entered European market.

Short descriptiontext

RealView Imaging is an Israeli medical technology company that has developed the HOLOSCOPE-i, the world's first FDA-cleared 3D holographic imaging system for interventional cardiology, using proprietary interference-based Digital Light Shaping™ technology for direct physician interaction with medical holograms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYoqne`am `illit, Israel
HQ citystring
Yoqne`am `illit
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical holographic imaging, interventional imaging systems, 3D medical visualization, holographic augmented reality, medical holography technology
Industry4 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHADAD
Surgical Visualization & OR Video Integration (4K/3D, Recording, Routing)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDACADAJ
Medical-Grade Displays (Diagnostic/Clinical)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
Medical Holographic Imaging Equipment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1HOLOSCOPE-i Medical Holographic System
TypeHardware Sales
Description

Sale of medical holographic imaging systems to hospitals and clinical facilities for use in interventional procedures. The system is designed for capital equipment procurement by healthcare institutions with interventional cardiology and imaging departments.

realviewimaging.com
2Customer Support and Service
TypeManaged Services
Description

The company maintains a customer portal for registered users, indicating ongoing support and potentially service/maintenance contracts for installed HOLOSCOPE-i systems.

realviewimaging.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1HOLOSCOPE
Description

Medical holographic product line providing full color, high resolution, dynamic and interactive 3D images in free space from medical volumetric data

realviewimaging.com
+2 more records
Core offering1 text field

RealView Imaging develops and sells the HOLOSCOPE-i system, the world's first FDA-cleared medical holographic imaging device that projects full-color, high-resolution, interactive 3D holograms in free space from volumetric medical data. The system uses proprietary Digital Light Shaping™ interference-based holography to enable physicians to visualize, touch, rotate, slice, mark, and measure holographic medical images at hand's reach during interventional procedures such as cardiac catheterization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First in human clinical trials evaluating live 3D holographic imaging in interventional cardiology successfully completed
+1 more record
Product overview1 text field

RealView Imaging offers a focused product portfolio centered on its HOLOSCOPE™-i system, the world's first commercially cleared medical holographic imaging system. The system is powered by the company's proprietary Digital Light Shaping™ technology, which uses true interference-based holography to generate full-color, high-resolution, dynamic 3D holograms in free space from volumetric medical imaging data. HOLOSCOPE-i enables physicians to visualize, interact with, and manipulate holographic medical images directly at hand's reach, supporting interventional procedures in cardiology and other specialties.

Product and service1 record
1HOLOSCOPE-i Medical Holographic Imaging System
CategoryMedical Imaging Equipment
Description

First FDA-cleared medical holographic imaging system providing full-color, high-resolution, dynamic and interactive 3D images in free space from any medical 3D volumetric data. Enables physicians to directly visualize, interact with, and manipulate holographic medical images (rotate, slice, mark, measure) at hand's reach during interventional procedures. Designed for interventional suites, hybrid operating rooms, and diagnostic clinics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-10-28
Description

World's first study to evaluate live 3D holographic imaging in interventional cardiology conducted in collaboration with Philips Healthcare. The partnership demonstrated first-in-human testing of RealView's technology with Philips' imaging systems, validating the clinical application of holographic imaging in cardiac procedures.

Strategic tierSupportingTypeTechnology or Integration
Description

RealView Imaging adopted Intel® RealSense™ technology for the HOLOSCOPE-i system, integrating depth sensing capabilities into the medical holographic platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

EchoPixel offers true 3D interactive medical visualization using glasses-free holographic-style displays, competing directly with RealView's HOLOSCOPE-i in interventional and surgical planning applications.

TypeDirect peer
Description

Surgical Theater provides VR-based 3D visualization for surgical planning and patient engagement, addressing the same interventional visualization use case as RealView with a different (VR headset) delivery model.

TypeDirect peer
Description

Augmedics develops AR visualization for spine surgery, competing in the AR/3D intra-procedural visualization category where RealView's HOLOSCOPE-i also operates.

TypeDirect peer
Description

Brainlab provides surgical visualization, planning, and navigation platforms used in interventional and image-guided procedures; a direct competitor for hospital visualization budgets.

TypeBroad incumbent
Description

Philips is a RealView partner and the dominant OEM in interventional cardiology imaging; if it integrated native holographic visualization into its Azurion platform, RealView could be displaced or relegated to a niche add-on.

TypeBroad incumbent
Description

GE HealthCare provides premium interventional imaging systems (e.g., Innova) and is positioned to bundle or develop competing AR/3D visualization features at scale.

TypeBroad incumbent
Description

Siemens Healthineers (ARTIS pheno, NAEOTOM) offers premium interventional imaging and visualization, a large incumbent competing for the same cath lab and hybrid OR capital budgets.

TypeBroad incumbent
Description

Medtronic offers image-guided therapy platforms and visualization tools in cardiology and neurosurgery; the acquirer of Ventor Medical (chaired by RealView Chairman Dr. Eckhouse) and a potential strategic acquirer.

TypeBroad incumbent
Description

Stryker's Surgical Navigation and Spine division provides intra-procedural visualization and AR guidance; competes for OR visualization capital expenditures across multiple specialties.

10Novarad
TypeEmerging player
Description

Novarad offers augmented reality surgical visualization (OpenSight) for pre-operative planning and intra-procedural guidance, an emerging competitor with overlapping medical AR visualization use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RealView Imaging

Medical Holographic Imaging Equipmentrealviewimaging.com

RealView Imaging is an Israeli medical technology company that has developed the HOLOSCOPE-i, the world's first FDA-cleared 3D holographic imaging system for interventional cardiology, using proprietary interference-based Digital Light Shaping™ technology for direct physician interaction with medical holograms.

What RealView Imaging does

RealView Imaging Ltd. is an Israeli medical technology company that has developed the world's first commercial 3D holographic display and interface system for medical imaging, anchored by its FDA-cleared HOLOSCOPE-i system. The company's core technology, Digital Light Shaping™, uses interference-based holography (originating from Nobel Prize-winning holography principles) together with Spatial Light Modulators to generate real-time, full-color, high-resolution 3D holograms in free space at hand-reach, eliminating the vergence-accommodation conflict associated with stereoscopic AR headsets. A complementary capability branded "Image Intimacy™" allows physicians to directly touch, rotate, slice, mark, and measure within the holographic image using Intel RealSense depth sensors.

The company's product portfolio is highly focused: the HOLOSCOPE-i system is the single commercial product, targeted at interventional cardiology procedures (catheterization, structural heart disease treatment, pre-surgical planning, and intra-procedural imaging guidance) in hospitals' interventional suites, hybrid operating rooms, and cardiac catheterization labs. A secondary target segment includes diagnostic clinics and medical education institutions needing advanced 3D visualization. Clinical validation has been supported by a first-in-human study conducted with Philips Healthcare.

RealView operates a direct enterprise sales motion, selling capital equipment to hospitals and clinical institutions, supplemented by ongoing customer support and service contracts (evidenced by a registered customer portal). The company is headquartered in Yokneam Illit, Israel, employs 11-50 people, and has raised approximately $25M across a 2014 Series B (LongTec China Ventures, $10M) and a 2020-2021 Series C (initial $10M from OurCrowd, expanded to $15M following FDA clearance). Geographic reach as of 2024 extends to Israel, the United States, and a newly entered European market.

RealView Imaging firmographics

Firmographics
Name
RealView Imaging
Legal name
RealView Imaging Ltd.
Website
https://realviewimaging.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
RealView Imaging is an Israeli medical technology company that has developed the HOLOSCOPE-i, the world's first FDA-cleared 3D holographic imaging system for interventional cardiology, using proprietary interference-based Digital Light Shaping™ technology for direct physician interaction with medical holograms.
Ownership category
akta.pro rank

RealView Imaging industry classification

Industry
Product category
Medical Holographic Imaging Equipment
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHADAD
Surgical Visualization & OR Video Integration (4K/3D, Recording, Routing)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDACADAJ
Medical-Grade Displays (Diagnostic/Clinical)

Keywords

  • Medical holographic imaging
  • Interventional imaging systems
  • 3D medical visualization
  • Holographic augmented reality
  • Medical holography technology

Where RealView Imaging is headquartered

Location

Headquarters

HQ city
Yoqne`am `illit
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

RealView Imaging business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. HOLOSCOPE-i Medical Holographic System: Sale of medical holographic imaging systems to hospitals and clinical facilities for use in interventional procedures. The system is designed for capital equipment procurement by healthcare institutions with interventional cardiology and imaging departments.
  2. Customer Support and Service: The company maintains a customer portal for registered users, indicating ongoing support and potentially service/maintenance contracts for installed HOLOSCOPE-i systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

RealView Imaging product offering

Product offering

Core offering

RealView Imaging develops and sells the HOLOSCOPE-i system, the world's first FDA-cleared medical holographic imaging device that projects full-color, high-resolution, interactive 3D holograms in free space from volumetric medical data. The system uses proprietary Digital Light Shaping™ interference-based holography to enable physicians to visualize, touch, rotate, slice, mark, and measure holographic medical images at hand's reach during interventional procedures such as cardiac catheterization.

Product overview

RealView Imaging offers a focused product portfolio centered on its HOLOSCOPE™-i system, the world's first commercially cleared medical holographic imaging system. The system is powered by the company's proprietary Digital Light Shaping™ technology, which uses true interference-based holography to generate full-color, high-resolution, dynamic 3D holograms in free space from volumetric medical imaging data. HOLOSCOPE-i enables physicians to visualize, interact with, and manipulate holographic medical images directly at hand's reach, supporting interventional procedures in cardiology and other specialties.

Differentiator

Problem solved

Functional benefit

Brands

  • HOLOSCOPE: Medical holographic product line providing full color, high resolution, dynamic and interactive 3D images in free space from medical volumetric data
  • HOLOSCOPE-i
  • Digital Light Shaping

Products and services

  • HOLOSCOPE-i Medical Holographic Imaging System First FDA-cleared medical holographic imaging system providing full-color, high-resolution, dynamic and interactive 3D images in free space from any medical 3D volumetric data. Enables physicians to directly visualize, interact with, and manipulate holographic medical images (rotate, slice, mark, measure) at hand's reach during interventional procedures. Designed for interventional suites, hybrid operating rooms, and diagnostic clinics.

Quantifiable outcome

  • First in human clinical trials evaluating live 3D holographic imaging in interventional cardiology successfully completed
  • +1 more outcomes

Companies that use RealView Imaging

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

RealView Imaging technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RealView Imaging partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • Philips HealthcarecoreStrategic or Co-development Partner · 28 October 2013World's first study to evaluate live 3D holographic imaging in interventional cardiology conducted in collaboration with Philips Healthcare. The partnership demonstrated first-in-human testing of RealView's technology with Philips' imaging systems, validating the clinical application of holographic imaging in cardiac procedures.
  • Intel CorporationsupportingTechnology or IntegrationRealView Imaging adopted Intel® RealSense™ technology for the HOLOSCOPE-i system, integrating depth sensing capabilities into the medical holographic platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

RealView Imaging competitors and assessment

Company assessment

Direct peers

  • EchoPixel: EchoPixel offers true 3D interactive medical visualization using glasses-free holographic-style displays, competing directly with RealView's HOLOSCOPE-i in interventional and surgical planning applications.
  • Surgical Theater: Surgical Theater provides VR-based 3D visualization for surgical planning and patient engagement, addressing the same interventional visualization use case as RealView with a different (VR headset) delivery model.
  • Augmedics: Augmedics develops AR visualization for spine surgery, competing in the AR/3D intra-procedural visualization category where RealView's HOLOSCOPE-i also operates.
  • Brainlab: Brainlab provides surgical visualization, planning, and navigation platforms used in interventional and image-guided procedures; a direct competitor for hospital visualization budgets.

Broad incumbents

  • Philips Healthcare (Image-Guided Therapy): Philips is a RealView partner and the dominant OEM in interventional cardiology imaging; if it integrated native holographic visualization into its Azurion platform, RealView could be displaced or relegated to a niche add-on.
  • GE HealthCare: GE HealthCare provides premium interventional imaging systems (e.g., Innova) and is positioned to bundle or develop competing AR/3D visualization features at scale.
  • Siemens Healthineers: Siemens Healthineers (ARTIS pheno, NAEOTOM) offers premium interventional imaging and visualization, a large incumbent competing for the same cath lab and hybrid OR capital budgets.
  • Medtronic: Medtronic offers image-guided therapy platforms and visualization tools in cardiology and neurosurgery; the acquirer of Ventor Medical (chaired by RealView Chairman Dr. Eckhouse) and a potential strategic acquirer.
  • Stryker (Surgical Navigation): Stryker's Surgical Navigation and Spine division provides intra-procedural visualization and AR guidance; competes for OR visualization capital expenditures across multiple specialties.

Emerging players

  • Novarad: Novarad offers augmented reality surgical visualization (OpenSight) for pre-operative planning and intra-procedural guidance, an emerging competitor with overlapping medical AR visualization use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

RealView Imaging social profiles

Digital presence

RealView Imaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RealView Imaging leadership team

Management profile

Number of profiles

Profiles1 record

RealView Imaging funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RealView Imaging M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RealView Imaging

What does RealView Imaging do?

RealView Imaging develops and sells the HOLOSCOPE-i system, the world's first FDA-cleared medical holographic imaging device that projects full-color, high-resolution, interactive 3D holograms in free space from volumetric medical data. The system uses proprietary Digital Light Shaping™ interference-based holography to enable physicians to visualize, touch, rotate, slice, mark, and measure holographic medical images at hand's reach during interventional procedures such as cardiac catheterization.

Is RealView Imaging a public or private company?

RealView Imaging is a private company. It is classified as venture growth investor backed and is currently operating.

When was RealView Imaging founded?

RealView Imaging was founded in 2013. It employs 11 to 50 people.

Where is RealView Imaging based?

RealView Imaging is headquartered in Yoqne`am `illit, Israel, in the Middle East region.

How does RealView Imaging make money?

Two revenue lines are on record. HOLOSCOPE-i Medical Holographic System is the primary driver. The others are customer Support and Service.

Who are RealView Imaging's main competitors?

Direct peers on record are EchoPixel, Surgical Theater, Augmedics and Brainlab. Broad incumbents are Philips Healthcare (Image-Guided Therapy), GE HealthCare, Siemens Healthineers, Medtronic and Stryker (Surgical Navigation). Novarad is listed as an emerging player.

Does RealView Imaging have an API?

No public API is recorded for RealView Imaging.

What industry is RealView Imaging in?

RealView Imaging's product category is Medical Holographic Imaging Equipment. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLACALAD, Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comScreenless Display Market to Reach $8.53 Billion by 2031 Amid Rising Adoption of AR Displays, Retinal Projection, and Voice InterfacesMordor Intelligence published a market research report projecting the global screenless display market will grow from USD 3.41 billion in 2025 to USD 8.53 billion by 2031, representing a compound annual growth rate of 16.52%. The report attributes growth to increasing adoption of augmented-reality windshields in vehicles, healthcare visualization technologies, defense applications, and ambient computing in consumer devices, while noting supply constraints in specialized optical materials and safety limits for retinal projection as moderating factors. Key industry players identified include Alphabet Inc., Sony Corporation, Microsoft Corporation, Eon Reality Inc., and Realview Imaging Ltd.Spherical InsightsTop 50 Companies in Global Digital Holography Market Forecast, News Report 2035A market research report published by Spherical Insights & Consulting projects the Global Digital Holography Market to grow from USD 4.0 billion in 2024 to USD 22.57 billion by 2035, representing a compound annual growth rate of 17.03% during the forecast period. Key growth drivers include rising demand for 3D imaging, advances in medical diagnostics, industrial inspection, AR/VR integration, and AI-enabled holographic technologies across healthcare, entertainment, and manufacturing sectors. The report identifies North America as generating the largest market demand while Asia Pacific is expected to be the fastest-growing region, with leading companies including EON Reality, RealView Imaging, and Geola Digital UAB driving innovation in holographic microscopy, medical imaging, and immersive visualization.FmiblogHolography in Medical Imaging Market to Skyrocket to USD 49.1 Billion by 2035 – FMIBlogThe holography in medical imaging market is projected to grow from USD 3.7 billion in 2025 to USD 49.1 billion by 2035, a 29.5% CAGR. RealView Imaging leads with a 22% share, and CT-based holography holds the top imaging modality share. India leads regional growth at 36.9% CAGR.Ken ResearchGlobal Holographic Display MarketThis is a market research industry report on the Global Holographic Display Market, valued at USD 10 billion, analyzing growth drivers, competitive landscape, and future outlook through 2030. The report identifies key market players including Microsoft Corporation, Holoxica Limited, RealView Imaging Ltd., Leia Inc., Qualcomm Inc., and others, while noting that the United States, Japan, and Germany dominate due to strong technological infrastructure. Market growth is driven by demand for immersive experiences in retail, healthcare, entertainment, and automotive sectors, though challenges include high production costs reaching up to $1.2 million per unit for high-end models and limited consumer awareness at 35%.Ken ResearchNorth America Holographic Imaging Market, Growth Opportunities & Future Outlook to 2030A market research report projects the North America Holographic Imaging Market will reach USD 3.6 billion by 2030, driven by advancements in medical imaging and expanding adoption in education and retail. Key growth factors include high-resolution 3D visualization capabilities for surgical guidance and diagnostics, while challenges involve high initial setup costs and technical limitations in real-time data transmission. The competitive landscape is led by companies such as RealView Imaging, Holoxica, and EchoPixel, with the United States dominating regional market dynamics due to robust healthcare infrastructure.Cognitive Market ResearchThe global hologram projector market size will be USD XX million in 2024.Cognitive Market Research published a report forecasting the global hologram projector market to reach USD 14,266 million by 2033, driven by demand for immersive experiences and optical advancements. The analysis highlights North America as the dominant region with over 40% market share and identifies interactive projectors as the fastest-growing segment. Key industry players such as Microsoft and RealView Imaging are cited for their strategic investments and regulatory approvals in medical and enterprise applications.DAICRealView Imaging Receives FDA for Holoscope-i Medical Holographic Imaging SystemRealView Imaging Ltd. received FDA 510(k) clearance for its Holoscope-i holographic imaging system, which creates interactive 3D medical holograms based on CT scans and 3D ultrasound data. This system, designed for clinician use without the need for head-mounted devices, aims to enhance visualization during interventional procedures and intends to expand commercial availability in North America and beyond. The Holoscope-i’s launch comes alongside the company's recent $15 million funding round for further advancements in medical imaging technology.FierceBiotechFDA clears 3D hologram tech for 'science-fiction' surgical planningThe FDA cleared RealView Imaging's Holoscope-i system, which projects 3D holograms of patient organs from CT and ultrasound scans. The device lets surgeons manipulate and measure anatomy without headsets. RealView plans commercial rollout and expansion to Europe and other countries.PR NewswireRealView Imaging Ltd., World Leader in Medical Holography, Receives FDA Clearance for its Groundbreaking HOLOSCOPE™-i Holographic SystemRealView Imaging Ltd. announced FDA 510(k) clearance for its HOLOSCOPE™-i holographic system, which creates spatially accurate, three-dimensional interactive medical holograms from standard CT scans and 3D ultrasound data without requiring head-mounted devices or special eyewear. The system, based on the company's proprietary Digital Light Shaping™ technology using true interference-based volumetric holography, is the first and only medical holography system of its kind and is designed for use during minimally-invasive interventional procedures. The company recently expanded its Series C financing round to $15 million and is now focused on commercialization in North America following this regulatory approval.PR NewswireWorldwide Medical Holography Industry to 2026 - The Emergence of Holography Technology to Represent Complex 3D Structures is Driving GrowthResearchAndMarkets.com announced the addition of a "Medical Holography Market 2020-2026" report, projecting considerable growth in the global medical holography market during the forecast period. Key growth drivers include the expanding clinical applications of holography and the emergence of technology to represent complex 3D structures, while high computational costs for processing holograms may restrain market growth. North America is expected to hold a significant market share due to high healthcare expenditure and adoption rates, with Asia-Pacific anticipated to show considerable growth driven by rising chronic disease prevalence.